ArticleThoracic cancer2023

Clinical outcomes of advanced NSCLC patients with different EGFR exon 19 deletion subtypes treated with first-line tyrosine kinase inhibitors: A single-center ambispective cohort study.

Yangchun Gu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.